TPN-672

TPN-672 is a novel small molecule antipsychotic drug candidate developed for the treatment of schizophrenia and other psychiatric disorders. It acts as a serotonin-dopamine receptor modulator with high affinity for several key receptors. Specifically, it functions as a potent serotonin 5-HT1A receptor agonist, dopamine D2/D3 receptor partial agonist, and serotonin 5-HT2A receptor antagonist[1][2][6]. Preclinical studies have demonstrated that TPN-672 can attenuate negative symptoms and cognitive deficits associated with schizophrenia more effectively than aripiprazole while exhibiting a favorable safety margin[2]. The drug may also possess antidepressant-like effects due to its action on serotonergic and dopaminergic pathways and its ability to enhance neurotrophic factors in the brain[6]. Clinical development has focused on oral administration in tablet form.

Other names

TPN672TPN-672TPN 672TPN672MATPN-672MATPN 672MATPN 672 maleateTPN672 maleateTPN-672 maleate